LadRx (LADX) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 11, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-15327
Entity Registrant Name	CytRx Corporation
Entity Central Index Key	0000799698
Entity Tax Identification Number	58-1642740
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	11726 San Vicente Blvd.
Entity Address, Address Line Two	Suite 650
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90049
City Area Code	(310)
Local Phone Number	826-5648
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		45,037,391

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 4,111,845	$ 6,769,603
Insurance claim receivable	100,000	200,000
Prepaid expenses and other current assets	479,054	1,310,382
Total current assets	4,690,899	8,279,985
Equipment and furnishings, net	26,061	32,784
Other assets	7,703	16,836
Operating lease right-of-use assets	306,871	397,172
Total assets	5,031,534	8,726,777
Current liabilities:
Accounts payable	1,210,369	1,470,652
Accrued expenses and other current liabilities	1,214,563	2,064,506
Current portion of operating lease liabilities	132,940	198,819
Total current liabilities	2,557,872	3,733,977
Operating lease liabilities, net of current portion	189,390	216,381
Preferred Stock, Series C 10% Convertible, $1,000 par value, 2,752 and 8,240 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	1,343,684	4,022,700
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $0.01 par value, 833,333 shares authorized, including 50,000 shares of Series B Junior Participating Preferred Stock; no shares issued and outstanding
Common stock, $0.001 par value, 62,393,940 shares authorized; 45,037,391 and 38,780,038 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	45,037	38,780
Additional paid-in capital	487,469,516	484,790,650
Accumulated deficit	(486,573,965)	(484,075,711)
Total stockholders’ equity	940,588	753,719
Total liabilities and stockholders’ equity	$ 5,031,534	$ 8,726,777

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Temporary equity, par value	$ 1,000	$ 1,000
Temporary equity, shares issued	2,752	8,240
Temporary equity, shares outstanding	2,752	8,240
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	833,333	833,333
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	62,393,940	62,393,940
Common stock, shares issued	45,037,391	38,780,038
Common stock, shares outstanding	45,037,391	38,780,038
Series C Convertible Preferred Stock [Member]
Preferred stock, dividend rate, percentage	10%	10%
Series B junior participating preferred stock [Member]
Preferred stock, shares authorized	50,000	50,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Licensing revenue
Expenses:
General and administrative	1,148,037	1,181,211	2,442,754	2,461,059
Loss from operations	(1,148,037)	(1,181,211)	(2,442,754)	(2,461,059)
Other income (loss):
Interest income	1,002	4,146	1,855	8,982
Forgiveness of accounts payable	353,565		353,565
Other income (loss), net	(306)	1,269	(2,353)	(3,022)
Net loss	(793,776)	(1,175,796)	(2,089,687)	(2,455,099)
Dividends paid on preferred shares	(202,567)		(408,567)
Net loss attributable to common stockholders	$ (996,343)	$ (1,175,796)	$ (2,498,254)	$ (2,455,099)
Total basic and diluted loss per share	$ (0.02)	$ (0.03)	$ (0.06)	$ (0.07)
Basic and diluted weighted-average shares outstanding	44,320,100	36,549,269	41,679,126	36,515,038

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss from operations	$ (2,089,687)	$ (2,455,099)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7,490	6,587
Stock-based compensation expense	6,104
Changes in assets and liabilities:
Insurance claim receivable	100,000	325,105
Prepaid expenses and other current assets	831,328	768,352
Other assets	9,133
Amortization of right-of-use asset	90,301	90,833
Accounts payable	(260,285)	(439,056)
Decrease in lease liabilities	(92,870)	(89,211)
Accrued expenses and other current liabilities	(849,939)	145,950
Net cash used in operating activities	(2,248,425)	(1,646,539)
Cash flows from investing activities:
Purchase of fixed assets	(766)
Net cash used in investing activities	(766)
Cash flows from financing activities
Preferred stock dividend	(408,567)
Proceeds from exercise of stock options		78,000
Net cash provided by (used in) financing activities	(408,567)	78,000
Net decrease in cash and cash equivalents	(2,657,758)	(1,568,539)
Cash and cash equivalents at beginning of period	6,769,603	10,003,375
Cash and cash equivalents at end of period	4,111,845	8,434,836
Supplemental disclosure of Cash Flow Information:
Conversion of Series C Preferred Stock to Common Stock	$ 2,679,019

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020		$ 36,480	$ 479,561,860	$ (470,727,380)	$ 8,870,960
Beginning balance, shares at Dec. 31, 2020		36,480,038
Net loss				(1,279,303)	(1,279,303)
Ending balance, value at Mar. 31, 2021		$ 36,480	479,561,860	472,006,683	7,591,657
Ending balance, shares at Mar. 31, 2021		36,480,038
Beginning balance, value at Dec. 31, 2020		$ 36,480	479,561,860	(470,727,380)	8,870,960
Beginning balance, shares at Dec. 31, 2020		36,480,038
Preferred dividend
Net loss					(2,455,099)
Ending balance, value at Jun. 30, 2021		$ 36,780	479,639,560	(473,182,479)	6,493,861
Ending balance, shares at Jun. 30, 2021		36,780,038
Beginning balance, value at Mar. 31, 2021		$ 36,480	479,561,860	472,006,683	7,591,657
Beginning balance, shares at Mar. 31, 2021		36,480,038
Exercise of stock options		$ 300	77,700		78,000
Exercise of stock options, shares		300,000
Preferred dividend
Net loss				(1,175,796)	(1,175,796)
Ending balance, value at Jun. 30, 2021		$ 36,780	479,639,560	(473,182,479)	6,493,861
Ending balance, shares at Jun. 30, 2021		36,780,038
Beginning balance, value at Dec. 31, 2021		$ 38,780	484,790,650	(484,075,711)	753,719
Beginning balance, shares at Dec. 31, 2021		38,780,038
Exercise of stock options		$ 21	(21)
Exercise of stock options, shares		21,404
Conversion of preferred shares		$ 4,682	2,006,609		2,011,351
Conversion of preferred shares, shares		4,681,819
Preferred dividend				(206,000)	(206,000)
Issuance of restricted stock for compensation			3,299		3,299
Net loss				(1,295,911)	(1,295,911)
Ending balance, value at Mar. 31, 2022		$ 43,483	486,800,597	(485,577,622)	1,266,458
Ending balance, shares at Mar. 31, 2022		43,483,261
Beginning balance, value at Dec. 31, 2021		$ 38,780	484,790,650	(484,075,711)	$ 753,719
Beginning balance, shares at Dec. 31, 2021		38,780,038
Exercise of stock options, shares					50,000
Preferred dividend					$ (408,567)
Net loss					(2,089,687)
Ending balance, value at Jun. 30, 2022		$ 45,037	487,469,516	(486,573,965)	940,588
Ending balance, shares at Jun. 30, 2022		45,037,391
Beginning balance, value at Mar. 31, 2022		$ 43,483	486,800,597	(485,577,622)	1,266,458
Beginning balance, shares at Mar. 31, 2022		43,483,261
Conversion of preferred shares		$ 1,554	666,114		667,668
Conversion of preferred shares, shares		1,554,130
Preferred dividend				(202,567)	(202,567)
Issuance of restricted stock for compensation			2,805		2,805
Net loss				(793,776)	(793,776)
Ending balance, value at Jun. 30, 2022		$ 45,037	$ 487,469,516	$ (486,573,965)	$ 940,588
Ending balance, shares at Jun. 30, 2022		45,037,391

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements at June 30, 2022 and for the three-month and six-month periods ended June 30, 2022 and 2021, respectively, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2021 have been derived from our audited financial statements as of that date. The consolidated financial statements included herein have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The consolidated financial statements should be read in conjunction with our audited financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”). Going Concern The Company’s condensed consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. During the six months ended June 30, 2022, the Company incurred a net loss of $ 2,089,687 2,248,425 486,573,965 The Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended December 31, 2021, has also expressed substantial doubt about the Company’s ability to continue as a going concern. At June 30, 2022, we had cash and cash equivalents and short-term investments of approximately $ 4.1 Use of Estimates Preparation of the Company’s consolidated financial statements in conformance with U.S. GAAP requires the Company’s management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The significant estimates in the Company’s consolidated financial statements relate to the valuation of equity awards, recoverability of deferred tax assets, and estimated useful lives of fixed assets, The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions. Stock Compensation The Company accounts for share-based awards to employees and nonemployees directors and consultants in accordance with the provisions of ASC 718, Compensation—Stock Compensation. Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Foreign Currency Remeasurement The U.S. dollar has been determined to be the functional currency for the net assets of our German operations. The transactions are recorded in the local currencies and are remeasured at each reporting date using the historical rates for nonmonetary assets and liabilities and current exchange rates for monetary assets and liabilities at the balance sheet date. Exchange gains and losses from the remeasurement of monetary assets and liabilities are recognized in other income (loss). The Company recognized a loss of approximately $ (10,900) (16,200) 3,500 (9,500) Basic and Diluted Net Loss Per Common Share Basic and diluted net loss per common share is computed based on the weighted-average number of common shares outstanding for the period. Diluted net income (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. Common share equivalents that could potentially dilute net loss per share in the future, and which were excluded from the computation of diluted loss per share, were as follows: Schedule of Shares Excluded from Computation of Diluted Loss Per Share 2022 2021 As of June 30, 2022 2021 Options to acquire common stock 1,847,611 2,862,700 Warrants to acquire common stock 4,167 4,167 Series C Convertible preferred stock 3,127,688 — Investment option 11,363,637 — Shares excluded from computation of diluted loss per shares 16,343,103 2,866,867 Fair Value Measurements Assets and liabilities recorded at fair value on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are as follows: Level 1 – quoted prices in active markets for identical assets or liabilities. Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date. We consider carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments. Our non-financial assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2022. The adoption of ASU 2016-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The adoption of ASU 2021-04 did not have any impact on the Company’s consolidated financial statement presentation or disclosures. Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (“SEC”) did not, or are not expected to, have a material impact on the Company’s consolidated financial statements and related disclosures.

Financing Under Security Purcha

Financing Under Security Purchase Agreement	6 Months Ended
	Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Financing Under Security Purchase Agreement	2. Financing Under Security Purchase Agreement On July 13, 2021, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor (the “Investor”) for aggregate gross proceeds of $ 10 9.2 2 0.88 1.76 8,240 10.00 1,000 8.24 9,363,637 0.88 The terms of the Preferred Stock include beneficial ownership limitations that preclude conversion that would result in the Investor owning in excess of 9.99% of the Company’s outstanding shares of common stock 11,363,637 10 0.88 The Company accounted for these transactions as a single transaction for accounting purposes and allocated total proceeds to the respective instruments based upon the relative fair value of each instrument. The Company determined that the relative fair value of (i) the 2,000,000 859,218 8,240 4,022,700 4,293,872 5,153,090 4,022,700 On October 1, 2021, the Company paid a quarterly 10 171,668 206,000 202,567 On March 15, 2022, at a special meeting of its stockholders which was originally opened and subsequently adjourned on September 23, 2021, the Company’s stockholders, by an affirmative vote of the majority of the Company’s outstanding shares of capital stock, approved the amendment to the Company’s Restated Certificate of Incorporation to effect an increase in the number of shares of authorized common stock, par value $ 0.001 41,666,666 62,393,940 On March 28, 2022, the Investor converted 4,120 4,681,819 1,368 1,554,130 Terms of Series C Preferred Stock Under the Certificate of the Designations, Powers, Preferences and Rights of Series C 10.00 41,666,666 1,000 0.88 The Certificate of Designations contains limitations that prevent the holder thereof from acquiring shares of common stock upon conversion that would result in the number of shares of common stock beneficially owned by such holder and its affiliates exceeding 9.99% of the total number of shares of common stock outstanding immediately after giving effect to the conversion (the “Beneficial Ownership Limitation”), except that upon notice from the holder to the Company, the holder may increase or decrease the amount of ownership of outstanding shares of common stock after converting the holder’s shares of Series C Preferred Stock, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of outstanding shares of the common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the shares of Series C Preferred Stock held by the holder and provided that any increase in the Beneficial Ownership Limitation shall not be effective until 61 days following notice to the Company Each holder of shares of Preferred Stock is entitled to receive dividends, commencing from the date of issuance of the Preferred Stock. Such dividends may be paid only when, as and if declared by the Board of Directors of the Company (the “Board”), out of assets legally available therefore, quarterly in arrears on the first day of January, April, July and October in each year, commencing on the date of issuance, at the dividend rate of 10.00 Under the Certificate of Designations, each share of Series C Preferred Stock carries a liquidation preference equal to the Series C Stated Value plus accrued and unpaid and accumulated dividends thereon. Such liquidation preference is payable upon certain change in control transactions and accordingly, this instrument is classified as mezzanine (temporary equity). The holders of the Series C Preferred Stock may vote their shares of Preferred Stock on an as-converted basis, subject to the Beneficial Ownership Limitation (which Beneficial Ownership Limitation shall be calculated on a basis which includes the number of shares of common stock which are issuable upon conversion of the unconverted Series C Stated Value beneficially owned by a holder or any of its affiliates or attribution parties on all matters submitted to the holders of common stock for approval). The Company may not take the following actions without the prior consent of the holders of at least a majority of the Preferred Stock then outstanding: (a) alter or change adversely the powers, preferences or rights given to the Preferred Stock or alter or amend the Certificate of Designations, (b) authorize or create any class of stock ranking as to dividends, redemption or distribution of assets upon a Liquidation (as defined in the Certificate of Designations) senior to, or otherwise pari passu Terms of Preferred Investment Option The Preferred Investment Option to purchase up to 11,363,637 0.88 Registration Rights Agreement In connection with the July 2021 Offerings, the Company entered into a registration rights agreement, dated as of July 13, 2021 (the “Registration Rights Agreement”), with the investor named therein, pursuant to which the Company will undertake to file, within five calendar days of the date of the filing of the proxy statement seeking the Stockholder Approval, a resale registration statement to register the shares of common stock issuable upon: (i) the conversion of the Preferred Stock sold in the Private Placement and (ii) the exercise of the Preferred Investment Option (the “Registrable Securities”); and to cause such registration statement to be declared effective under the Securities Act as promptly as possible after the filing thereof, but in any event no later than 75 days following the pricing date of this offering, or no later than 105 days following such date in the event of a “full review” by the SEC, and shall use its reasonable best efforts to keep such registration statement continuously effective under the Securities Act until the date that all Registrable Securities covered by such registration statement have been sold or are otherwise able to be sold pursuant to Rule 144. The Registration Rights Agreement provides for liquidated damages to the extent that the Company does not file or maintain a registration statement in accordance with the terms thereof. The registration rights agreement entered into between us and the Investor on July 13, 2021, contains a triggering event which would require us to pay to any holder of the Preferred Stock an amount in cash, as partial liquidated damages and not as a penalty, on a monthly basis equal to the product of 2.0 24 1,977,600 18 During the year ended December 31, 2021, the Company did not have enough shares of authorized common stock to issue the shares of common stock issuable upon the exercise or conversion of the Registrable Securities, as applicable. For the year ended December 31, 2021, the Company attempted, but was unsuccessful, to obtain its stockholders’ approval for the increase in its shares of authorized common stock at a special meeting that was originally opened and subsequently adjourned on September 23, 2021, and accordingly, the Company was unable to meet its registration rights obligation as of December 31, 2021. As such, the Company recognized an aggregate of approximately $ 1.1 615,123 41,666,666 63,227,273

Series D Preferred Stock

Series D Preferred Stock	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Series D Preferred Stock	3. Series D Preferred Stock On May 19, 2022, the Board declared a dividend of one one-thousandth of a share of Series D Preferred Stock, par value $ 0.01 On July 27, 2022, at the Company’s 2022 Annual Meeting of Stockholders, the Company’s stockholders approved a proposal to authorize the Board, in its discretion but prior to July 26, 2023, to amend the Company’s Restated Certificate of Incorporation to effect a reverse stock split of all of the outstanding shares of the Company’s Common Stock, at a ratio in the range of 1-for-2 to 1-for-100, with such ratio to be determined by the Board, and all outstanding shares of Series D Preferred Stock were automatically redeemed no

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases
Leases	4. Leases We lease office space and office copiers related primarily to the administrative activities. The Company accounts for leases under ASC 842, Leases, In January 2020, the Company signed a new four 2,771 February 29, 2024 five 13,855 3.5 1,370 2.5 715,310 66,271 As of June 30, 2022, the balance of right-of-use assets was approximately $ 307,000 322,000 Future minimum lease payments under non-cancelable operating leases under ASC 842 as of June 30, 2022 are as follows: Schedule of Future Minimum Lease Payments Operating July 2022 – June 2023 $ 197,600 July 2023 – June 2024 134,690 Total future minimum lease payments 332,290 Less: present value adjustment 9,960 Operating lease liabilities at June 30, 2022 322,330 Less: current portion of operating lease liabilities 132,940 Operating lease liabilities, net of current portion $ 189,390 The components of rent expense and supplemental cash flow information related to leases for the period are as follows: Schedule of Rent Expense and Supplemental Cash Flow Information Related to Leases Period Ended Lease Cost Operating lease cost (included in General and administrative expenses in the Company’s condensed Consolidated Statements of Operations) $ 99,462 Other information Cash paid for amounts included in the measurement of lease liabilities for the period ended June 30, 2022 $ 91,894 Weighted average remaining lease term – operating leases (in years) 1.7 Average discount rate 3.6 %

Stock Based Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock Based Compensation	5. Stock Based Compensation The Company has a 2008 Stock Incentive Plan (“2008 Plan”) under which 5 1.8 0.8 November 20, 2018 In November 2019, the Company adopted a 2019 Stock Incentive Plan (“2019 Plan”) under which 5.4 0.5 November 14, 2029 There were no During the six months ended June 30, 2022, 50,000 21,404 Presented below is our stock option activity: Schedule of Stock Options Activity Six Months Ended June 30, 2022 Number of Options (Employees) Number of Options (Non-Employees) Total Number of Options Weighted-Average Exercise Price Outstanding at January 1, 2022 2,462,830 365,000 2,827,830 $ 8.09 Exercised (50,000 ) — (50,000 ) $ 0.26 Forfeited or expired (930,219 ) — (930,219 ) $ 10.65 Outstanding at June 30, 2022 1,482,611 365,000 1,847,611 $ 7.02 Exercisable at June 30, 2022 1,482,611 365,000 1,847,611 $ 7.02 The following table summarizes significant ranges of outstanding stock options under our plans at June 30, 2022: Schedule of Ranges of Stock Options Range of Exercise Prices Number of Weighted-Average Weighted-Average Number of Options Weighted-Average Weighted-Average $ 0.26 1.00 500,000 7.46 $ 0.26 500,000 7.46 $ 0.26 $ 1.01 3.00 634,006 5.21 $ 1.96 634,006 5.21 $ 1.96 $ 3.01 15.00 454,166 2.77 $ 11.92 454,166 2.77 $ 11.92 $ 15.01 42.42 259,439 1.75 $ 23.82 254,439 1.75 $ 23.82 1,847,611 5.28 $ 3.32 1,847,611 5.28 $ 3.32 The Company recorded no stock compensation costs in either periods ended June 30, 2022 or June 30, 2021 as all options had previously vested. At June 30, 2022, there was no unrecognized compensation expense related to unvested stock options. The aggregate intrinsic value of the outstanding options and options vested as of June 30, 2022 was $ 0 At June 30, 2022 and June 30, 2021, the Company had 4,167 10.44 4,167 no Restricted Stock On December 15, 2021, the Company granted to Jennifer Simpson, who serves on our Board of Directors, 25,000 11,200 6,104 5,148

Stockholder Protection Rights P

Stockholder Protection Rights Plan	6 Months Ended
	Jun. 30, 2022
Stockholder Protection Rights Plan
Stockholder Protection Rights Plan	6. Stockholder Protection Rights Plan On December 13, 2019, the Board of Directors of the Company, authorized and declared a dividend of one right (a “Right”) for each of the Company’s issued and outstanding shares of common stock, par value $ 0.001 0.01 5.00 On November 12, 2020, the Board approved an amendment and restatement of the Original Rights Agreement (as amended and restated, the “Amended and Restated Rights Agreement”) to effect certain changes to the Original Rights Agreement, including (i) reducing the duration to a term of three years, subject to certain earlier expiration as described in more detail below, and (ii) lowering the beneficial ownership threshold at which a person or group of persons becomes an Acquiring Person (as defined below) to 4.95% or more of the Company’s outstanding shares of Common Stock, subject to certain exceptions. The Amended and Restated Rights Agreement is designed to discourage (i) any person or group of persons from acquiring beneficial ownership of more than 4.95% of the Company’s shares of Common Stock and (ii) any existing stockholder currently beneficially holding 4.95% or more of the Company’s shares of Common Stock from acquiring additional shares of the Company’s Common Stock The purpose of the Amended and Restated Rights Agreement is to protect value by preserving the Company’s ability to utilize its net operating losses and certain other tax attributes (collectively, the “Tax Benefits”) to offset potential future income tax obligations. The Company’s ability to use its Tax Benefits would be substantially limited if it experiences an “ownership change,” as such term is defined in Section 382 of the Internal Revenue Code of 1986, as amended (the “Tax Code”). A corporation generally will experience an ownership change if the percentage of the corporation’s stock owned by its “5-percent shareholders,” as defined in Section 382 of the Tax Code, increases by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. The Amended and Restated Rights Agreement is intended to reduce the likelihood the Company would experience an ownership change under Section 382 of the Tax Code. The Rights will not be exercisable until the earlier to occur of (i) the close of business on the tenth business day after a public announcement or filing that a person or group of affiliated or associated persons has become an “Acquiring Person,” which is defined as a person or group of affiliated or associated persons that, at any time after the date of the Amended and Restated Rights Agreement, has acquired, or obtained the right to acquire, beneficial ownership of 4.95% or more of the Company’s outstanding shares of Common Stock, subject to certain exceptions or (ii) the close of business on the tenth business day after the commencement of, or announcement of an intention to commence, a tender offer or exchange offer the consummation of which would result in any person becoming an Acquiring Person (the earlier of such dates being called the “Distribution Date”) ( provided however The Rights, which are not exercisable until the Distribution Date, will expire at or prior to the earliest of (i) the close of business on November 16, 2023; (ii) the time at which the Rights are redeemed pursuant to the Amended and Restated Rights Agreement; (iii) the time at which the Rights are exchanged pursuant to the Amended and Restated Rights Agreement; (iv) the time at which the Rights are terminated upon the occurrence of certain mergers or other transactions approved in advance by the Board; and (v) the close of business on the date set by the Board following a determination by the Board that (x) the Amended and Restated Rights Agreement is no longer necessary or desirable for the preservation of the Tax Benefits or (y) no Tax Benefits are available to be carried forward or are otherwise available (the earliest of (i), (ii), (iii), (iv) and (v) is referred to as the “ Expiration Date Each share of Preferred Stock will be entitled, when, as and if declared, to a preferential per share quarterly dividend payment equal to the greater of (i) $1.00 per share or (ii) an amount equal to 1,000 times the dividend declared per share of Common Stock. Each share of Preferred Stock will entitle the holder thereof to 1,000 votes on all matters submitted to a vote of the stockholders of the Company. In the event of any merger, consolidation or other transaction in which shares of Common Stock are converted or exchanged, each share of Preferred Stock will be entitled to receive 1,000 times the amount received per one share of Common Stock The Purchase Price payable, and the number of shares of Preferred Stock or other securities or property issuable, upon exercise of the Rights are each subject to adjustment from time to time to prevent dilution (i) in the event of a stock dividend on, or a subdivision, combination or reclassification of the Preferred Stock, (ii) upon the grant to holders of the Preferred Stock of certain rights or warrants to subscribe for or purchase Preferred Stock or convertible securities at less than the then-current market price of the Preferred Stock or (iii) upon the distribution to holders of the Preferred Stock of evidences of indebtedness or assets (excluding regular periodic cash dividends or dividends payable in Preferred Stock) or of subscription rights or warrants (other than those referred to above). The number of outstanding Rights and the number of one one-thousandths of a share of Preferred Stock issuable upon exercise of each Right are also subject to adjustment in the event of a stock split, reverse stock split, stock dividends and other similar transactions involving the Common Stock. In the event that any person or group of affiliated or associated persons becomes an Acquiring Person, each holder of a Right, other than the Rights beneficially owned by the Acquiring Person, affiliates and associates of the Acquiring Person and certain transferees thereof (which will thereupon become null and void), will thereafter have the right to receive upon exercise of a Right that number of shares of Common Stock having a market value of two times the Purchase Price. In the event that, after a person or a group of affiliated or associated persons has become an Acquiring Person, the Company is acquired in a merger or other business combination transaction, or 50% or more of the Company’s assets or earning power are sold, proper provision will be made so that each holder of a Right will thereafter have the right to receive, upon the exercise thereof at the then-current purchase price of the Right, that number of shares of common stock of the acquiring company having a market value at the time of that transaction equal to two times the Purchase Price. With certain exceptions, no adjustment in the Purchase Price will be required unless such adjustment would require an increase or decrease of at least one percent (1%) in the Purchase Price. No fractional shares of Preferred Stock will be issued (other than fractions which are integral multiples of one one-thousandth of a share of Preferred Stock, which may, at the election of the Company, be evidenced by depositary receipts) and, in lieu thereof, an adjustment in cash will be made based on the market price of the Preferred Stock on the trading day immediately prior to the date of exercise. At any time after any person or group of affiliated or associated persons becomes an Acquiring Person and prior to the acquisition of beneficial ownership by such Acquiring Person of 50% or more of the outstanding shares of Common Stock, the Board, at its option, may exchange each Right (other than Rights owned by such person or group of affiliated or associated persons which will have become void), in whole or in part, at an exchange ratio of one share of Common Stock per outstanding Right (subject to adjustment). In connection with any exercise or exchange of the Rights, no holder of a Right will be entitled to receive shares of Common Stock if receipt of such shares would result in such holder, together with such holder’s affiliates and associates, beneficially owning more than 4.95% of the then-outstanding Common Stock (such shares, the “Excess Shares”) and the Board determines that such holder’s receipt of Excess Shares would jeopardize or endanger the value or availability of the Tax Benefits or the Board otherwise determines that such holder’s receipt of Excess Shares is not in the best interests of the Company. In lieu of such Excess Shares, such holder will only be entitled to receive cash or a note or other evidence of indebtedness with a principal amount equal to the then-current market price of the Common Stock multiplied by the number of Excess Shares that would otherwise have been issuable. At any time before the Distribution Date, the Board may redeem the Rights in whole, but not in part, at a price of $ 0.001 Immediately upon the action of the Board electing to redeem or exchange the Rights, the Company shall make a public announcement thereof, and upon such election, the right to exercise the Rights will terminate and the only right of the holders of Rights will be to receive the Redemption Price. Until a Right is exercised or exchanged, the holder thereof, as such, will have no rights as a stockholder of the Company, including, without limitation, the right to vote or to receive dividends. The Board may amend or supplement the Amended and Restated Rights Agreement without the approval of any holders of Rights, including, without limitation, in order to (a) cure any ambiguity, (b) correct inconsistent provisions, (c) alter time period provisions, including the Expiration Date, or (d) make additional changes to the Amended and Restated Rights Agreement that the Board deems necessary or desirable. However, from and after the date any person or group of affiliated or associated persons becomes an Acquiring Person, the Amended and Restated Rights Agreement may not be supplemented or amended in any manner that would adversely affect the interests of the holders of Rights.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Commitments Aldoxorubicin We have an agreement with Vergell Medical (formerly with KTB Tumorforschungs GmbH) (“Vergell”) for the exclusive license of patent rights held by Vergell for the worldwide development and commercialization of aldoxorubicin. Under the agreement, we must make payments to Vergell in the aggregate of $ 7.5 ● commercially reasonable royalties based on a percentage of net sales (as defined in the agreement); ● a percentage of non-royalty sub-licensing income (as defined in the agreement); and ● milestones of $ 1 In the event that we must pay a third party in order to exercise our rights to the intellectual property under the agreement, we are entitled to deduct a percentage of those payments from the royalties due Vergell, up to an agreed upon cap. Arimoclomol The agreement relating to our worldwide rights to arimoclomol provides for our payment of up to an aggregate of $ 3.65 12.8 5.2 Innovive Under the merger agreement by which we acquired Innovive, we agreed to pay the former Innovive stockholders a total of up to approximately $ 18.3 As of June 30, 2022 and December 31, 2021, no amounts were due under the above agreements. Contingencies We apply the disclosure provisions of ASC 460, Guarantees The Company evaluates developments in legal proceedings and other matters on a quarterly basis. The Company records accruals for loss contingencies to the extent that the Company concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. In December 2019, a novel strain of coronavirus, COVID-19, was first identified in China and has surfaced in several regions across the world. In March 2020, the disease was declared a pandemic by the World Health Organization. As the situation with Covid-19 continues to evolve, the companies which are working to further develop and commercialize our products, ImmunityBio and Orphazyme, could be materially and adversely affected by the risks, or the public perception of the risks, related to this pandemic. Among other things, the active and planned clinical trials by ImmunityBio and Orphazyme and their regulatory approvals, if any, may be delayed or interrupted, which could delay or adversely affect the Company’s potential receipt of milestone and royalty payments within the disclosed time periods and increase expected costs. As of the date of this filing, senior management and administrative staff are working primarily remotely and will return to their offices at a yet to be determined date.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	8. Subsequent Events As discussed on Note 3, on July 27, 2022, both the Initial Redemption and the Subsequent Redemption occurred. As a result, no

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements at June 30, 2022 and for the three-month and six-month periods ended June 30, 2022 and 2021, respectively, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2021 have been derived from our audited financial statements as of that date. The consolidated financial statements included herein have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The consolidated financial statements should be read in conjunction with our audited financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”).
Going Concern	Going Concern The Company’s condensed consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. During the six months ended June 30, 2022, the Company incurred a net loss of $ 2,089,687 2,248,425 486,573,965 The Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended December 31, 2021, has also expressed substantial doubt about the Company’s ability to continue as a going concern. At June 30, 2022, we had cash and cash equivalents and short-term investments of approximately $ 4.1
Use of Estimates	Use of Estimates Preparation of the Company’s consolidated financial statements in conformance with U.S. GAAP requires the Company’s management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The significant estimates in the Company’s consolidated financial statements relate to the valuation of equity awards, recoverability of deferred tax assets, and estimated useful lives of fixed assets, The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.
Stock Compensation	Stock Compensation The Company accounts for share-based awards to employees and nonemployees directors and consultants in accordance with the provisions of ASC 718, Compensation—Stock Compensation. Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting
Foreign Currency Remeasurement	Foreign Currency Remeasurement The U.S. dollar has been determined to be the functional currency for the net assets of our German operations. The transactions are recorded in the local currencies and are remeasured at each reporting date using the historical rates for nonmonetary assets and liabilities and current exchange rates for monetary assets and liabilities at the balance sheet date. Exchange gains and losses from the remeasurement of monetary assets and liabilities are recognized in other income (loss). The Company recognized a loss of approximately $ (10,900) (16,200) 3,500 (9,500)
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share Basic and diluted net loss per common share is computed based on the weighted-average number of common shares outstanding for the period. Diluted net income (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. Common share equivalents that could potentially dilute net loss per share in the future, and which were excluded from the computation of diluted loss per share, were as follows: Schedule of Shares Excluded from Computation of Diluted Loss Per Share 2022 2021 As of June 30, 2022 2021 Options to acquire common stock 1,847,611 2,862,700 Warrants to acquire common stock 4,167 4,167 Series C Convertible preferred stock 3,127,688 — Investment option 11,363,637 — Shares excluded from computation of diluted loss per shares 16,343,103 2,866,867
Fair Value Measurements	Fair Value Measurements Assets and liabilities recorded at fair value on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are as follows: Level 1 – quoted prices in active markets for identical assets or liabilities. Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date. We consider carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments. Our non-financial assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2022. The adoption of ASU 2016-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The adoption of ASU 2021-04 did not have any impact on the Company’s consolidated financial statement presentation or disclosures. Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (“SEC”) did not, or are not expected to, have a material impact on the Company’s consolidated financial statements and related disclosures.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Schedule of Shares Excluded from Computation of Diluted Loss Per Share	Schedule of Shares Excluded from Computation of Diluted Loss Per Share 2022 2021 As of June 30, 2022 2021 Options to acquire common stock 1,847,611 2,862,700 Warrants to acquire common stock 4,167 4,167 Series C Convertible preferred stock 3,127,688 — Investment option 11,363,637 — Shares excluded from computation of diluted loss per shares 16,343,103 2,866,867

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases
Schedule of Future Minimum Lease Payments	Future minimum lease payments under non-cancelable operating leases under ASC 842 as of June 30, 2022 are as follows: Schedule of Future Minimum Lease Payments Operating July 2022 – June 2023 $ 197,600 July 2023 – June 2024 134,690 Total future minimum lease payments 332,290 Less: present value adjustment 9,960 Operating lease liabilities at June 30, 2022 322,330 Less: current portion of operating lease liabilities 132,940 Operating lease liabilities, net of current portion $ 189,390
Schedule of Rent Expense and Supplemental Cash Flow Information Related to Leases	The components of rent expense and supplemental cash flow information related to leases for the period are as follows: Schedule of Rent Expense and Supplemental Cash Flow Information Related to Leases Period Ended Lease Cost Operating lease cost (included in General and administrative expenses in the Company’s condensed Consolidated Statements of Operations) $ 99,462 Other information Cash paid for amounts included in the measurement of lease liabilities for the period ended June 30, 2022 $ 91,894 Weighted average remaining lease term – operating leases (in years) 1.7 Average discount rate 3.6 %

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Options Activity	Presented below is our stock option activity: Schedule of Stock Options Activity Six Months Ended June 30, 2022 Number of Options (Employees) Number of Options (Non-Employees) Total Number of Options Weighted-Average Exercise Price Outstanding at January 1, 2022 2,462,830 365,000 2,827,830 $ 8.09 Exercised (50,000 ) — (50,000 ) $ 0.26 Forfeited or expired (930,219 ) — (930,219 ) $ 10.65 Outstanding at June 30, 2022 1,482,611 365,000 1,847,611 $ 7.02 Exercisable at June 30, 2022 1,482,611 365,000 1,847,611 $ 7.02
Schedule of Ranges of Stock Options	The following table summarizes significant ranges of outstanding stock options under our plans at June 30, 2022: Schedule of Ranges of Stock Options Range of Exercise Prices Number of Weighted-Average Weighted-Average Number of Options Weighted-Average Weighted-Average $ 0.26 1.00 500,000 7.46 $ 0.26 500,000 7.46 $ 0.26 $ 1.01 3.00 634,006 5.21 $ 1.96 634,006 5.21 $ 1.96 $ 3.01 15.00 454,166 2.77 $ 11.92 454,166 2.77 $ 11.92 $ 15.01 42.42 259,439 1.75 $ 23.82 254,439 1.75 $ 23.82 1,847,611 5.28 $ 3.32 1,847,611 5.28 $ 3.32

Schedule of Shares Excluded fro

Schedule of Shares Excluded from Computation of Diluted Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from computation of diluted loss per shares	16,343,103	2,866,867
Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from computation of diluted loss per shares	3,127,688
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from computation of diluted loss per shares	1,847,611	2,862,700
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from computation of diluted loss per shares	4,167	4,167
Investment Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from computation of diluted loss per shares	11,363,637

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Accounting Policies [Abstract]
Net loss	$ 793,776	$ 1,295,911	$ 1,175,796	$ 1,279,303	$ 2,089,687	$ 2,455,099
Cash in operatings					2,248,425	1,646,539
Accumulated deficit	486,573,965				486,573,965		$ 484,075,711
Cash and cash equivalents and short-term investments	4,100,000				4,100,000
Foreign currency transaction gain (loss)	$ (10,900)		$ 3,500		$ (16,200)	$ (9,500)

Financing Under Security Purc_2

Financing Under Security Purchase Agreement (Details Narrative) - USD ($)					6 Months Ended	12 Months Ended
	Apr. 01, 2022	Jan. 02, 2022	Oct. 01, 2021	Jul. 13, 2021	Jun. 30, 2022	Dec. 31, 2021	May 15, 2022	Mar. 28, 2022	Mar. 15, 2022	Mar. 14, 2022	Sep. 23, 2021	Sep. 22, 2021	Dec. 13, 2019
Purchase price per share													$ 5
Common stock, par value					$ 0.001	$ 0.001			$ 0.001				$ 0.001
Common stock, shares authorized					62,393,940	62,393,940			63,227,273	41,666,666	62,393,940	41,666,666
Stated value per share					$ 1,000	$ 1,000
Loss contingency, damages sought, value						$ 1,100,000
Loss contingency accrual provision					$ 615,123
Preferred Investment Option [Member]
Option to purchase common stock				11,363,637
Option exercisable price				$ 0.88
Series C Convertible Preferred Stock [Member]
Preferred stock dividend rate percentage				10%	10%	10%
Conversion price				$ 0.88
Preferred stock contract terms				The Certificate of Designations contains limitations that prevent the holder thereof from acquiring shares of common stock upon conversion that would result in the number of shares of common stock beneficially owned by such holder and its affiliates exceeding 9.99% of the total number of shares of common stock outstanding immediately after giving effect to the conversion (the “Beneficial Ownership Limitation”), except that upon notice from the holder to the Company, the holder may increase or decrease the amount of ownership of outstanding shares of common stock after converting the holder’s shares of Series C Preferred Stock, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of outstanding shares of the common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the shares of Series C Preferred Stock held by the holder and provided that any increase in the Beneficial Ownership Limitation shall not be effective until 61 days following notice to the Company
Common stock, shares authorized				41,666,666
Stated value per share				$ 1,000
Investor [Member]
Shares issued upon conversion							1,554,130	4,681,819
Number of shares converted							1,368	4,120
Securities Purchase Agreement [Member] | Common Stock [Member]
Number of shares issued, value				$ 859,218
Number of shares issued				2,000,000
Securities Purchase Agreement [Member] | Series C Convertible Preferred Stock [Member]
Number of shares issued, value				$ 4,022,700
Number of shares issued				8,240
Fair value of the common stock and Preferred Investment Option				$ 4,022,700
Securities Purchase Agreement [Member] | Preferred Investment Option [Member]
Fair value of the Preferred Investment Option				4,293,872
Fair value of the common stock and Preferred Investment Option				5,153,090
Securities Purchase Agreement [Member] | Investor [Member]
Gross proceeds from issuance of equity				10,000,000
Number of shares issued, value				$ 9,200,000
Number of shares issued				2,000,000
Purchase price per share				$ 0.88
Proceeds from issuance of common stock				$ 1,760,000
Securities Purchase Agreement [Member] | Investor [Member] | Preferred Investment Option [Member]
Option to purchase common stock				11,363,637
Option indexed to issuers equity shares value				$ 10,000,000
Option exercisable price				$ 0.88
Securities Purchase Agreement [Member] | Investor [Member] | Series C Convertible Preferred Stock [Member]
Number of shares issued				8,240
Purchase price per share				$ 1,000
Preferred stock dividend rate percentage			10%	10%
Proceeds from issuance of private placement				$ 8,240,000
Shares issued upon conversion				9,363,637
Conversion price				$ 0.88
Preferred stock contract terms				The terms of the Preferred Stock include beneficial ownership limitations that preclude conversion that would result in the Investor owning in excess of 9.99% of the Company’s outstanding shares of common stock
Dividend paid	$ 202,567	$ 206,000	$ 171,668
Registration Rights Agreement [Member]
Percentage of liquidated damages				2%
Liquidated damages				$ 1,977,600
Percentage of interest payable on liquidated damages				18%
Registration Rights Agreement [Member] | Maximum [Member]
Percentage of liquidated damages				24%

Series D Preferred Stock (Detai

Series D Preferred Stock (Details Narrative) - $ / shares	Jul. 27, 2022	May 19, 2022	Nov. 12, 2020
Class of Stock [Line Items]
Dividend description			Each share of Preferred Stock will be entitled, when, as and if declared, to a preferential per share quarterly dividend payment equal to the greater of (i) $1.00 per share or (ii) an amount equal to 1,000 times the dividend declared per share of Common Stock. Each share of Preferred Stock will entitle the holder thereof to 1,000 votes on all matters submitted to a vote of the stockholders of the Company. In the event of any merger, consolidation or other transaction in which shares of Common Stock are converted or exchanged, each share of Preferred Stock will be entitled to receive 1,000 times the amount received per one share of Common Stock
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Dividend description		On May 19, 2022, the Board declared a dividend of one one-thousandth of a share of Series D Preferred Stock, par value $0.01 per share (“Series D Preferred Stock”), for each outstanding share of Company’s Common Stock to stockholders of record at 5:00 p.m. Eastern Time on May 20, 2022
Dividend rate per share		$ 0.01
Series D Preferred Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Description of stock split ratio	On July 27, 2022, at the Company’s 2022 Annual Meeting of Stockholders, the Company’s stockholders approved a proposal to authorize the Board, in its discretion but prior to July 26, 2023, to amend the Company’s Restated Certificate of Incorporation to effect a reverse stock split of all of the outstanding shares of the Company’s Common Stock, at a ratio in the range of 1-for-2 to 1-for-100, with such ratio to be determined by the Board, and all outstanding shares of Series D Preferred Stock were automatically redeemed
Preferred stock, shares outstanding	0

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Leases
July 2022 – June 2023	$ 197,600
July 2023 – June 2024	134,690
Total future minimum lease payments	332,290
Less: present value adjustment	9,960
Operating lease liabilities at June 30, 2022	322,330
Less: current portion of operating lease liabilities	132,940	$ 198,819
Operating lease liabilities, net of current portion	$ 189,390	$ 216,381

Schedule of Rent Expense and Su

Schedule of Rent Expense and Supplemental Cash Flow Information Related to Leases (Details)	6 Months Ended
	Jun. 30, 2022 USD ($)
Leases
Operating lease cost	$ 99,462
Cash paid for lease liabilities	$ 91,894
Weighted average remaining lease term - operating leases (in years)	1 year 8 months 12 days
Average discount rate	3.60%

Leases (Details Narrative)

Leases (Details Narrative)	1 Months Ended
	Feb. 29, 2020 USD ($)	Jan. 31, 2020 USD ($) ft²	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Lease term		4 years
Area of land | ft²		2,771
Lease expiration date		Feb. 29, 2024
Extended term		5 years
Payments for rent	$ 1,370	$ 13,855
Annual percentage increased in monthly rent	2.50%	3.50%
Right of use asset	$ 715,310		$ 306,871	$ 397,172
Lease liability obligation			$ 322,330
Revision of Prior Period, Reclassification, Adjustment [Member]
Right of use asset	$ 66,271

Schedule of Stock Options Activ

Schedule of Stock Options Activity (Details)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock Options, Outstanding beginning	2,827,830
Weighted Average Exercise Price Options, Outstanding at beginning of year | $ / shares	$ 8.09
Stock Options, Exercised	(50,000)
Weighted Average Exercise Price Options, Exercised | $ / shares	$ 0.26
Stock Options, Forfeited or expired	(930,219)
Weighted Average Exercise Price Options, Forfeited or expired | $ / shares	$ 10.65
Stock Options, Outstanding ending	1,847,611
Weighted Average Exercise Price Options, Outstanding end of year | $ / shares	$ 7.02
Stock Options, Exercisable at end of year	1,847,611
Weighted Average Exercise Price Options, Exercisable at end of year | $ / shares	$ 7.02
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock Options, Outstanding beginning	2,462,830
Stock Options, Exercised	(50,000)
Stock Options, Forfeited or expired	(930,219)
Stock Options, Outstanding ending	1,482,611
Stock Options, Exercisable at end of year	1,482,611
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock Options, Outstanding beginning	365,000
Stock Options, Exercised
Stock Options, Forfeited or expired
Stock Options, Outstanding ending	365,000
Stock Options, Exercisable at end of year	365,000

Schedule of Ranges of Stock Opt

Schedule of Ranges of Stock Options (Details) - Share-Based Payment Arrangement, Option [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding | shares	1,847,611
Weighted-Average Remaining Contractual Life (years)	5 years 3 months 10 days
Weighted-Average Exercise Price	$ 3.32
Number of Options Exercisable | shares	1,847,611
Weighted-Average Remaining Contractual Life (years)	5 years 3 months 10 days
Weighted-Average Exercise Price, Options Exercisable	$ 3.32
Exercise Price Range One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower Range	0.26
Range of Exercise Prices, Upper Range	$ 1
Number of Options Outstanding | shares	500,000
Weighted-Average Remaining Contractual Life (years)	7 years 5 months 15 days
Weighted-Average Exercise Price	$ 0.26
Number of Options Exercisable | shares	500,000
Weighted-Average Remaining Contractual Life (years)	7 years 5 months 15 days
Weighted-Average Exercise Price, Options Exercisable	$ 0.26
Exercise Price Range Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower Range	1.01
Range of Exercise Prices, Upper Range	$ 3
Number of Options Outstanding | shares	634,006
Weighted-Average Remaining Contractual Life (years)	5 years 2 months 15 days
Weighted-Average Exercise Price	$ 1.96
Number of Options Exercisable | shares	634,006
Weighted-Average Remaining Contractual Life (years)	5 years 2 months 15 days
Weighted-Average Exercise Price, Options Exercisable	$ 1.96
Exercise Price Range Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower Range	3.01
Range of Exercise Prices, Upper Range	$ 15
Number of Options Outstanding | shares	454,166
Weighted-Average Remaining Contractual Life (years)	2 years 9 months 7 days
Weighted-Average Exercise Price	$ 11.92
Number of Options Exercisable | shares	454,166
Weighted-Average Remaining Contractual Life (years)	2 years 9 months 7 days
Weighted-Average Exercise Price, Options Exercisable	$ 11.92
Exercise Price Range Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower Range	15.01
Range of Exercise Prices, Upper Range	$ 42.42
Number of Options Outstanding | shares	259,439
Weighted-Average Remaining Contractual Life (years)	1 year 9 months
Weighted-Average Exercise Price	$ 23.82
Number of Options Exercisable | shares	254,439
Weighted-Average Remaining Contractual Life (years)	1 year 9 months
Weighted-Average Exercise Price, Options Exercisable	$ 23.82

Stock Based Compensation (Detai

Stock Based Compensation (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	Dec. 15, 2021	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Nov. 30, 2019
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding stock options				1,847,611		2,827,830
Options granted				0	0
Stock options exercised				50,000
Aggregate intrinsic value of outstanding options and vested options				$ 0
Warrant outstanding			4,167	4,167	4,167
Weighted average exercise price			$ 10.44	$ 10.44	$ 10.44
Stock based compensation expense				$ 6,104
Unamortized stock compensation				$ 5,148
Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options exercised		21,404	300,000
Common stock exchange for shares				21,404
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Aggregate intrinsic value of outstanding options and vested options				$ 0
Restricted Stock [Member] | Steven Kriegsman [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares granted	25,000
Shares issued, shares				11,200
Stock based compensation expense				$ 6,104
2008 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved for issuance				5,000,000
Outstanding stock options				1,800,000
Plan expiration date				Nov. 20, 2018
2008 Stock Incentive Plan [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding				800,000
2019 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved for issuance							5,400,000
Outstanding stock options				500,000
Plan expiration date				Nov. 14, 2029

Stockholder Protection Rights_2

Stockholder Protection Rights Plan (Details Narrative) - $ / shares	Nov. 12, 2020	Jun. 30, 2022	Mar. 15, 2022	Dec. 31, 2021	Dec. 13, 2019
Stockholder Protection Rights Plan
Common Stock, stated value per share		$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred stock, par value		$ 0.01		$ 0.01	0.01
Purchase price per share					$ 5
Stockholders rights description	the Board approved an amendment and restatement of the Original Rights Agreement (as amended and restated, the “Amended and Restated Rights Agreement”) to effect certain changes to the Original Rights Agreement, including (i) reducing the duration to a term of three years, subject to certain earlier expiration as described in more detail below, and (ii) lowering the beneficial ownership threshold at which a person or group of persons becomes an Acquiring Person (as defined below) to 4.95% or more of the Company’s outstanding shares of Common Stock, subject to certain exceptions. The Amended and Restated Rights Agreement is designed to discourage (i) any person or group of persons from acquiring beneficial ownership of more than 4.95% of the Company’s shares of Common Stock and (ii) any existing stockholder currently beneficially holding 4.95% or more of the Company’s shares of Common Stock from acquiring additional shares of the Company’s Common Stock
Preferred stock, dividend payment terms	Each share of Preferred Stock will be entitled, when, as and if declared, to a preferential per share quarterly dividend payment equal to the greater of (i) $1.00 per share or (ii) an amount equal to 1,000 times the dividend declared per share of Common Stock. Each share of Preferred Stock will entitle the holder thereof to 1,000 votes on all matters submitted to a vote of the stockholders of the Company. In the event of any merger, consolidation or other transaction in which shares of Common Stock are converted or exchanged, each share of Preferred Stock will be entitled to receive 1,000 times the amount received per one share of Common Stock
Preferred stock, redemption price per share	$ 0.001

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	May 31, 2022	Jun. 30, 2022
Kem Pharm [Member]
Product Liability Contingency [Line Items]
Cash consideration from sale of assets	$ 12,800
Liabilities assumed	$ 5,200
Aldoxorubicin [Member]
Product Liability Contingency [Line Items]
Milestone payment, amount		$ 1,000
Aldoxorubicin [Member] | Maximum [Member]
Product Liability Contingency [Line Items]
Milestone payment, amount		7,500
Arimoclomol [Member]
Product Liability Contingency [Line Items]
Milestone payment, amount		3,650
Innovivel [Member]
Product Liability Contingency [Line Items]
Future earnout merger consideration		$ 18,300

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Jul. 27, 2022 shares
Subsequent Event [Member] | Series D Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares outstanding	0